Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahlers, Georgios Bakalos, Tarek Hassanein, Jovan Basho, Gentian Shabanaj, Arjan Harxhi, Nabil Debzi, Nawel Afredj, Nawal Guessab, Nadir Mahindad, Hassene Mahiou, Magda AissaouiJihad Al Qameesh, Zuhal Al Ghandoor, Collins Assene, Boris Bastens, Christian Brixko, Mike Cool, Chantal De Galocsy, Jean Delwaide, Christophe George, Pierre Laukens, Veronique Lefebvre, Jean Pierre Mulkay, Frederik Nevens, Benoit Servais, Hans Van Vlierberghe, Yves Horsmans, Jean Henrion, Dirk Sprengers, Peter Michielsen, Stefan Bourgeois, Luc Lasser, Philippe Langlet, Geert Robaeys, Jean Paul Martinet, Philippe Warzee, Paul Hoste, Hendrik Reynaert, Irène Juriens, Jochen Decaestecker, Filip Van Der Meersch, Filip Janssens, Sead Ahmetagic, Antonija Verhaz, Milenko Bevanda, Lejla Calkic, Nevzeta Ibrahimpasic, Rusmir Mesihovic, Carlos Eduardo Mello, Fernando Jose Ruiz, Elson Martins Junior, Maria Lucia Ferraz, Giovanni Silva, Claudio Mendes, Andre Lyra, Mariliza Henrique Silva, Geisa Gomide, Julio Cesar Fernandes, Patricia Pereira, Maria Cassia Correa, Rosangela Teixeira, Ayman Yousry, Abdelfatah Hanno, Mamdouh Gabr, Ashraf Omar, Gamal Esmat, Stilianos Karatapanis, Vassiliki Nikolopoulou, Grigoris Giannoulis, Spilios Manolakopoulos, Ioannis Elefsiniotis, Christos Drakoulis, Dimitrios Dimitroulopoulos, Stilianos Kanatakis, Ioannis Ketikoglou, Konstantinos Mimidis, Nikolaos Evgenidis, Euaggelos Akriviades, Irini Vafiadi-Zoubouli, Epameinondas Tsianos, Maria Mela, Eleni Orfanou, Georgios Mousoulis, Ioannis Karagiannis, Emmanuel Manesis, Marta Varga, Elemér Nemesánszky, Katalin Fried, János Schuller, Ferenc Szalay, Gabriella Lengyel, Istvan Tornai, Tivadar Banyai, Miklos Lesch, Istvan Nagy, Judit Gervain, Anna Tusnadi, Ferenc Schneider, László Szentgyörgyi, Bela Hunyady, Aron Vincze, Gyula Tolvaj, Istvan Varkonyi, Erzsébet Makkai, Judit Enyedi, Istvan Racz, Péter Hausinger, Zsuzsanna Váczi, Árpád Patai, Zsófia Ozsvár, Lilla Lakner, Pál Ribiczey, Ajay Bhalla, Sanjay Somani, Rosang Luaia, Padaki Rao, Mathew Philip, Parimal Lawate, Aabha Nagral, Ajit Sood, Samir Parikh, Shahin Merat, Mohsen Nassiri-Toosi, Seyed Moayed Alavian, Mohammad Reza Zali, Nasser Ebrahimi Daryani, Davide Drenaggi, Adolfo Francesco Attili, Franco Bandiera, Paolo Bassi, Giorgio Bellati, Stefano Bellantani, Maurizia Brunetto, Savino Bruno, Francesco Castelli, Roberto Castellacci, Anna Maria Cattelan, Massimo Colombo, Antonio Craxi, Salvatore D'angelo, Silvia Colombo, Luigi Demelia, Giovanni Di Perri, Antonio Di Giacomo, Carlo Ferrari, Daniela Francisci, Katia Casinelli, Roberto Ganga, Chiara Costa, Alessandra Mangia, Francesco Paolo Russo, Filippo Matarazzo, Giuseppe Mazzella, Maurizio Mazzeo, Massimo Memoli, Marzia Montalbano, Giuseppe Montalto, Alessandro Pieri, Nicola Passariello, Antonio Picciotto, Antonello Pietrangelo, Mario Pirisi, Tiziana Quirino, Giovanni Raimondo, Gian Ludovico Rapaccini, Giuliano Rizzardini, Mario Rizzetto, Maurizio Russello, Giuseppe Sabusco, Teresa Santantonio, Giorgio Soardo, Alessandri Amedea, Gabriella Verucchi, Francesco Vinelli, Anna Linda Zignego, Massimo Zuin, Antonio Ascione, Maria Vinci, Maria Graziella Pigozzi, Paolo Tundo, Giorgio Maria Saracco, Pietro Amoroso, Massimo Andreoni, Cosimo Colletta, Elke Erne, Angelo Salomone Megna, Alberto Biglino, Piergiorgio Chiriaco, Giuseppe Foti, Giancarlo Spinzi, Emilio D'amico, Seung Woon Paik, Sang Hoon Ahn, Yun Nah Lee, Yoonjun Kim, Jinmo Yang, Sang Young Han, Rosh Varghese, Abeer Al Gharabally, Haifa Askar, Ala Sharara, Cesar Yaghi, Antoine Abou Rached, Zaher Houmani, Fouad Zaarour, Ahmad Dohaibi, Ljubomir Ivanovski, Nenad Joksimovic, Zaigham Abbas, Sadik Memon, Aftab Mohsin, Siddiq Masood, Zahid Hashmi, Waldemar Halota, Zbigniew Deron, Wlodzimierz Mazur, Robert Flisiak, Artur Lipczynski, Joanna Musialik, Anna Piekarska, Krystyna Augustyniak, Barbara Baka-Cwierz, Krzysztof Simon, Andrzej Gietka, Hanna Berak, Jerzy Sieklucki, Danuta Radowska, Bronislawa Szlauer, Tomasz Piekos, Iwona Olszok, Maciej Jablkowski, Grazyna Orszulak, Iwona Warakomska, Maria João Aleixo, Cristina Valente, Guilherme Macedo, Rui Sarmento-Castro, Fausto Roxo, Telo Faria, Kamal Mansinho, Jorge Velez, José Presa Ramos, Horácio Guerreiro, Sara Alberto, Carlos Monteverde, Fátima Serejo, Paula Peixe, José Malhado, Manuela Curescu, Adrian Streinu-Cercel, Florin Caruntu, Hara Livia, Liliana Preotescu, Victoria Arama, Ioan Ancuta, Liana Gheorghe, Carol Stanciu, Anca Trifan, Monica Acalovschi, Vasile Andreica, Oliviu Pascu, Monica Lencu, Ioan Sporea, Dan Olteanu, Florentina Ionita-Radu, Carmen Fierbinteanu-Braticevici, Adriana Motoc, Rodica Silaghi, Marioara Musat, Felicia Coman, Marioara Stan, Cristina Cijevschi, Egidia Miftode, Dragan Delic, Rada Jesic, Darko Nozic, Petar Svorcan, Milotka Fabri, Ljiljana Konstantinovic, Mijomir Pelemis, Goran Jankovic, Zoran Todorovic, Aleksandar Nagorni, Viera Kupcova, Lubomir Skladany, Maria Szantova, Dusan Krkoska, Peter Jarcuska, Ivan Schreter, Marian Oltman, Jana Bocakova, Ivan Bunganic, Jozef Holoman, Alain Giguere, Ahmed Mohamed Saleh Abdou

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

Original languageEnglish
Article numbere0151703
JournalPLoS One
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort'. Together they form a unique fingerprint.

Cite this